Sartorius Stedim Biotech is currently covered by 19 sell-side analysts. The following list shows banks and securities firms that publish regular research reports on Sartorius Stedim Biotech.
Shares
Here you will find information on Sartorius Stedim Biotech shares (DIM).
Click here for Sartorius preference shares (SRT3) and Sartorius ordinary shares (SRT)
Stock Chart
Stock Chart
Shares Overview
Shares Overview
ISIN | FR0013154002 |
Stock exchange | Euronext Paris |
Market segment | Local Securities - Compartment A (Large Caps) |
Indixes | SBF 120 | CAC Next 20 | CAC Large 60 | CAC All-Tradable | CAC All Shares | CAC Healthcare | MSCI France | STOXX Europe 600 |
Capital stock | 19,466,081 euros |
Number of shares | 97,330,405 |
- thereof Sartorius AG | 71.5% |
- thereof free float | 28.5% |
Voting rights | ~166.0 million |
- thereof Sartorius AG | ~83.0% |
- thereof free float | ~17.0% |
Institution | Analyst |
Alpha Value | Virendra Chauhan |
Barclays | Charles Pitman-King |
Berenberg | Sam England |
Bernstein | Delphine Le Louet |
CIC Market Solutions | Arnaud Cadart |
Exane | Odysseas Manesiotis |
Goldman Sachs | James Quigley |
Gilbert Dupont | Guillaume Cuvillier |
HSBC | Shubhangi Gupta |
Kepler Chevreux | Oliver Reinberg |
Intron Health | Naresh Chouhan |
Jefferies | James Vane-Tempest |
JP Morgan | Richard Vosser |
Morgan Stanley | Thibault Boutherin |
Morningstar | Max Jousma |
Nephron | Tom DeBourcy |
Oddo BHF | Oliver Metzger |
RBC Capital Markets | Charles Weston |
UBS | Matthew Weston |
Disclaimer
Sartorius does not provide consensus data on its own website but redirects to Vara website.
Sartorius is covered by various German and international financial analysts, who provide their own research analyses and earnings estimates in respect of Sartorius Stedim Biotech SA. The most recent consensus is collected and provided by Vara Research and contains evaluations and estimates of these financial analysts. The consensus contains forward-looking statements, which are based on the current estimates and assumptions exclusively given by the participating analysts. Forward-looking statements are not to be understood as in any way guaranteeing that those expectations will turn out to be accurate. Future performance and the results achieved by Sartorius Stedim Biotech SA and its affiliated companies depend on a number of risks and uncertainties such as the future economic and market environment. Most of these factors are outside Sartorius’ control and cannot be accurately estimated in advance.
The consensus is not complied by Sartorius, and Sartorius does not control, change or censor it. Therefore, Sartorius shall not be liable for any deviation between the consensus and the company’s financial results. The development of the consensus by Vara Research is independent and not influenced by Sartorius.
Sartorius solely provides links to Vara Research GmbH website, but it does not make any recommendations of its own. The publication of this information does not imply that Sartorius makes any representations, warranties, or accepts or confirms such information, conclusions, or recommendations. The company therefore assumes no responsibility for the accuracy or completeness of these estimates and does not undertake to supervise, update or revise them, or even to comment or correct them. This is a complete autonomous application of Vara Research and Sartorius assumes no action, nor bears any responsibility regarding the information contained.
Data published by Vara Research remains under the entire Vara Research responsibilities. By accessing these Vara Research’s data, you acknowledge that you have been made aware by Sartorius of the risks involved in using Vara Research’s data.
You, hereby agree to release Sartorius Stedim Biotech S.A., its subsidiaries and affiliates, their directors, officers and other representatives from any and all liabilities, whether directly or by way of indemnification, and you waive any and all claims for any direct and/or indirect, consequential damages, of any nature whatsoever (including in particular financial losses) arising directly or indirectly, from the access and use of Vara Research’s data and Vara Research’s website.
You are now leaving the Sartorius website to go to an independent third-party website.
By clicking the “I agree” button below, you will be transferred to a webpage which contains information that is maintained by Vara Research. The service presents consensus estimates and recommendations that are calculated and compiled regularly and independently by Vara Research. Sartorius has no control over the linked webpage and its content.
The consensus is collected and provided by Vara Research and can be found by clicking on the “I agree” button below.
By clicking to the “i agree” button below, you confirm your understanding of the above disclaimer and agree to all of its terms.
Shareholder Structure
Sartorius Stedim Biotech S.A.’s issued capital amounted to €19.5 million as of February 07, 2024, and was divided into 97,330,405 shares, each with a calculated par value of €0.20. As some of the shares convey double voting rights, there were a total of 165,581,058 voting rights as of the reporting date.